Article

Open Access | Editorial

Cancer Drug Resist 2018;1:198-9. 10.20517/cdr.2018.29 © The Author(s) 2018.

Acknowledgement to reviewers of Cancer Drug Resistance in 2018

Views: 1121 | Downloads: 771 | Cited: 0

Cancer Drug Resistance Editorial Office

OAE Publishing Inc., Chaoyang District, Beijing 100027, China.

Correspondence Address: OAE Publishing Inc., Suite 601, Tower A, TYG Center, C2 North Road, East 3rd Ring Road, Chaoyang District, Beijing 100027, China. E-mail: editorial@cdrjournal.com

Received: 3 Dec 2018 | Accepted: 7 Dec 2018 | Published: 19 Dec 2018

Science Editors: Godefridus J. Peters, Aamir Ahmad | Copy Editor: Cai-Hong Wang | Production Editor: Huan-Liang Wu

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The editors of the Cancer Drug Resistance would like to take this opportunity to express their sincere gratitude to the reviewers and guest editors for assessing manuscripts in 2018 [Table 1].

Table 1

Names of reviewers and guest editors

Names
Amstutz, Ursula	Jansen, Gerrit
Ahmad, Aamir	Jiang, Zhao
Balboni, Beatrice	Joerger, Markus
Ciriza, Jesús	Kwok, Hang Fai
Cloos, Jacqueline	Link, Wolfgang
Del Re, Marzia	Marchesi, Federica
El Hassouni, Btissame	Matsuura, Yoshiyuki
Fenton, Tim	Michaelis, Martin
Fiandalo, Michael	Mini, Enrico
Firuzi, Omid	Nobili, Stefania
Gan, Boyi	Nowak-Sliwinska, Patrycja
Garajová, Ingrid	Pasternak, Amy
Garrett, Michelle	Perego, Paola
Giovannetti, Elisa	Phillips, Roger M
Gong, Li	Pore, Milind
Griffiths, Elizabeth	Rodriguez, Jose Antonio
Huang, Shiliang	Rosière, Rémi
Huisman, M.C.	Wass, Mark
Hussain, Suleman	Zaffaroni, Nadia

The listed reviewers have our sincere gratitude. They can also get their Reviewer Recognition Certificates by building their peer review profiles on Publons (https://publons.com).

Declarations

Authors’ contributions

Writing and revision of the article and approved the final version: Cancer Drug Resistance Editorial Office

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Cite This Article

OAE Style

Cancer Drug Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resist 2018;1:198-9. http://dx.doi.org/10.20517/cdr.2018.29

AMA Style

Cancer Drug Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resistance. 2018; 1(4): 198-9. http://dx.doi.org/10.20517/cdr.2018.29

Chicago/Turabian Style

Cancer Drug Resistance Editorial Office, . 2018. "Acknowledgement to reviewers of Cancer Drug Resistance in 2018" Cancer Drug Resistance. 1, no.4: 198-9. http://dx.doi.org/10.20517/cdr.2018.29

ACS Style

Cancer Drug, Resistance Editorial Office. Acknowledgement to reviewers of Cancer Drug Resistance in 2018. Cancer Drug Resist. 2018, 1, 198-9. http://dx.doi.org/10.20517/cdr.2018.29

Views

1121

Downloads

771

Citations

Comments

Open Access Review

Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

DOI: 10.20517/cdr.2023.97

Amanda Reyes, Tanya Siddiqi

Available online: 26 Nov 2023

Open Access Review

Supramolecular host-guest nanosystems for overcoming cancer drug resistance

DOI: 10.20517/cdr.2023.77

Sha Wu, ... Jiong Zhou

Available online: 21 Nov 2023

Open Access Review

Emerging roles of 3D-culture systems in tackling tumor drug resistance

DOI: 10.20517/cdr.2023.93

Amin Nikdouz

, Francesca Orso

Available online: 20 Nov 2023

Open Access Review

Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies

DOI: 10.20517/cdr.2023.58

Rachel SJ Wong, ... Joline SJ Lim

Available online: 16 Nov 2023

Open Access Review

Unlocking antitumor immunity with adenosine receptor blockers

DOI: 10.20517/cdr.2023.63

Victoria A. Remley

, ... Julien Dimastromatteo

Available online: 24 Oct 2023

Open Access Review

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

DOI: 10.20517/cdr.2023.78

Jia-Wen Chen, ... Guo-Qing Chen

Available online: 18 Oct 2023

Open Access Original Article

Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity

DOI: 10.20517/cdr.2023.62

Hannah Zaryouh

, ... An Wouters

Available online: 16 Oct 2023

Open Access Review

Drug resistance in glioblastoma: from chemo- to immunotherapy

DOI: 10.20517/cdr.2023.82

Sachin Sharma, ... Tao Sun

Available online: 10 Oct 2023

Open Access Review

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

DOI: 10.20517/cdr.2023.39

Lindsay Gurska, Kira Gritsman

Available online: 25 Sep 2023

Open Access Review

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer

DOI: 10.20517/cdr.2023.48

Kenneth Sooi, ... Natalie Ngoi

Available online: 24 Sep 2023

Comments

Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.